1. Clinical & Scientific Overview
Oxaliplatin (TIP-MED-000561, Reference Code [ONC-12]) is classified under
Oncology & Antineoplastic Medicines as a Platinum Alkylating-Like Agent • Third-Generation Diaminocyclohexane (DACH) Platinum Complex.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Eloxatin (Sanofi India), Oxitan (Fresenius Kabi Oncology), Xalipat (Sun Pharma)
Lyophilised Powder / Solution for IV Infusion: 50 mg, 100 mg vials
Oncology Specialisation & Cytotoxic Safety Protocol
Platinum Alkylating-Like Agent
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: FOLFOX: 85 mg/m2 IV over 2 hours every 14 days; CAPOX: 130 mg/m2 IV over 2 hours every 21 days.
Signature Dose-Limiting Toxicities & Organ Monitoring: BIPHASIC PERIPHERAL NEUROPATHY: (1) Acute Cold-Triggered Neurosensory Dysaesthesia (85–90% — perioral numbness, jaw spasm, and pharyngolaryngeal dysaesthesia/feeling of difficulty swallowing triggered by cold drinks or cold air within hours of infusion) and (2) Cumulative Chronic Sensory Ataxic Neuropathy above 780–850 mg/m2.
Extravasation, Premedication & Safe Cytotoxic Handling: CRITICAL PHARMACEUTICAL INCOMPATIBILITY: NEVER reconstitute or dilute Oxaliplatin with 0.9% Sodium Chloride or chloride-containing solutions (chloride ions displace the oxalate ligand and degrade the drug — dilute STRICTLY in 5% Dextrose / D5W); counsel patients to avoid cold drinks, ice, and touching freezer items for 5 days post-infusion.
3. Mechanism of Action & Pharmacodynamics
Bulky 1,2-diaminocyclohexane (DACH) carrier ligand forms bulky DNA intrastrand cross-links that evade mismatch repair recognition and confer non-cross-resistance with cisplatin and carboplatin.
4. Therapeutic Indications & Evidence-Supported Uses
- Stage III Adjuvant and Metastatic Colorectal Carcinoma (FOLFOX and CAPOX regimens)
- Gastric and Pancreatic Adenocarcinoma (FOLFIRINOX / FLOT)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): FOLFOX: 85 mg/m2 IV over 2 hours every 14 days; CAPOX: 130 mg/m2 IV over 2 hours every 21 days.
Administration & Meal Timing: FOLFOX: 85 mg/m2 IV over 2 hours every 14 days; CAPOX: 130 mg/m2 IV over 2 hours every 21 days.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Oxaliplatin or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: BIPHASIC PERIPHERAL NEUROPATHY: (1) Acute Cold-Triggered Neurosensory Dysaesthesia (85–90% — perioral numbness, jaw spasm, and pharyngolaryngeal dysaesthesia/feeling of difficulty swallowing triggered by cold drinks or cold air within hours of infusion) and (2) Cumulative Chronic Sensory Ataxic Neuropathy above 780–850 mg/m2.
8. Adverse Effects Profile
- BIPHASIC PERIPHERAL NEUROPATHY: (1) Acute Cold-Triggered Neurosensory Dysaesthesia (85–90% — perioral numbness, jaw spasm, and pharyngolaryngeal dysaesthesia/feeling of difficulty swallowing triggered by cold drinks or cold air within hours of infusion) and (2) Cumulative Chronic Sensory Ataxic Neuropathy above 780–850 mg/m2.
- BIPHASIC PERIPHERAL NEUROPATHY: (1) Acute Cold-Triggered Neurosensory Dysaesthesia (85–90% — perioral numbness, jaw spasm, and pharyngolaryngeal dysaesthesia/feeling of difficulty swallowing triggered by cold drinks or cold air within hours of infusion) and (2) Cumulative Chronic Sensory Ataxic Neuropathy above 780–850 mg/m2.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- BIPHASIC PERIPHERAL NEUROPATHY: (1) Acute Cold-Triggered Neurosensory Dysaesthesia (85–90% — perioral numbness, jaw spasm, and pharyngolaryngeal dysaesthesia/feeling of difficulty swallowing triggered by cold drinks or cold air within hours of infusion) and (2) Cumulative Chronic Sensory Ataxic Neuropathy above 780–850 mg/m2.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: CRITICAL PHARMACEUTICAL INCOMPATIBILITY: NEVER reconstitute or dilute Oxaliplatin with 0.9% Sodium Chloride or chloride-containing solutions (chloride ions displace the oxalate ligand and degrade the drug — dilute STRICTLY in 5% Dextrose / D5W); counsel patients to avoid cold drinks, ice, and touching freezer items for 5 days post-infusion.
Pharmacist Patient Counselling Points:
- CRITICAL PHARMACEUTICAL INCOMPATIBILITY: NEVER reconstitute or dilute Oxaliplatin with 0.9% Sodium Chloride or chloride-containing solutions (chloride ions displace the oxalate ligand and degrade the drug — dilute STRICTLY in 5% Dextrose / D5W); counsel patients to avoid cold drinks, ice, and touching freezer items for 5 days post-infusion.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: CRITICAL PHARMACEUTICAL INCOMPATIBILITY: NEVER reconstitute or dilute Oxaliplatin with 0.9% Sodium Chloride or chloride-containing solutions (chloride ions displace the oxalate ligand and degrade the drug — dilute STRICTLY in 5% Dextrose / D5W); counsel patients to avoid cold drinks, ice, and touching freezer items for 5 days post-infusion.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.